The annual meeting of the American Society für Clinical Oncology (ASCO) took place again in Chicago. New results of clinical studies with advanced stage melanoma was presented. Dr. Okamoto reports from the post ASCO meeting where key results were highlighted.

See also: Dr. Okamoto on Facebook

Dr. Okamoto informs about improved survival of advanced stage melanoma

Until a few years ago, DTIC (chemotherapy) has been used as standard therapy in advanced stage melanoma with a poor efficacy for more than 35 years. The overall survival of the treated patients was 10 months. Now, with novel regimen which show even improved efficacy in combination, survival of patients could be significantly improved to 25 months. The ipilimumab and nivolumab combination (both antibodies against a cell surface antigen) might prove to be even more promising.


Please contact our office per phone under +43 1 40114, EXT 57015702 or 5703, by email to, or by filling out the electronic  contact form!

Contact inquiry

  • (Number on your ECARD. In case you do not have one, please enter your birthdate, e.g. 21.02.1964 - The social security number is not used for billing. It is used for identification in case of an appointment. )
  • (i.e. WGKK, SVA, BVA, KFA - In case you are not insured by the Austrian "Krankenkasse", please enter the name of your insurance. You also have the choice to enter „none“)
  • Please note that we can only answer inquiries with correctly completed mandatory fields.

    I hereby accept to be contacted by phone and email by the private practice Dr. Okamoto and that my data is stored. The Privacy Policy applies.
  • This field is for validation purposes and should be left unchanged.